For instance, the effective time frame for treating NSCLC with first-generation epidermal growth factor receptor (EGFR) TKIs does not exceed one year.6 In addition, a small proportion of tumor cells are primarily resistant to TKIs. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.